Standout Papers

Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 337... 2020 2026 2022 2024319
  1. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients (2020)
    Abi Vijenthira, Inna Y. Gong et al. Blood
  2. Antibody–drug conjugates: in search of partners of choice (2023)
    Jesús Fuentes‐Antrás, Sofia Genta et al. Trends in cancer

Immediate Impact

55 standout
Sub-graph 1 of 22

Citing Papers

From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy
2025 Standout
AXL signaling in cancer: from molecular insights to targeted therapies
2025 Standout
1 intermediate paper

Works of Abi Vijenthira being referenced

Antibody–drug conjugates: in search of partners of choice
2023 Standout
Cost-Effectiveness Analysis of Frontline Polatuzumab-Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone and/or Second-Line Chimeric Antigen Receptor T-Cell Therapy Versus Standard of Care for Treatment of Patients With Intermediate- to High-Risk Diffuse Large B-Cell Lymphoma
2022

Author Peers

Author Last Decade Papers Cites
Abi Vijenthira 398 119 129 311 40 809
Javier López‐Jiménez 222 130 224 206 59 699
Lauren B. Smith 203 86 141 143 57 901
Rishi S. Kotecha 218 100 217 115 70 813
Christophe Piguet 154 102 341 116 30 748
Supratik Basu 221 94 469 111 47 805
Min Liu 149 106 43 162 41 871
Elliott Perlin 224 293 210 78 58 894
Xian Zhang 445 19 50 350 53 935
Wendy Mills 257 85 182 121 17 672
Julia M. Cruz 268 75 178 75 36 742

All Works

Loading papers...

Rankless by CCL
2026